Posthemorrhagic hydrocephalus treatment

• Inhibition of histone deacetylase 6 activity mitigates neurological impairment and post-hemorrhagic hydrocephalus after intraventricular hemorrhage by modulating pyroptosis and autophagy pathways
• First insights into the utilisation of the M.BLUE() device for post-haemorrhagic hydrocephalus treatment
• Ultra-low-field portable MRI for assessing ventricular size in pediatric hydrocephalus: a feasibility study
• Effect of shunt-dependency on long-term outcome after aneurysmal subarachnoid hemorrhage: a post-hoc analysis of the EARLYDRAIN prospective patient cohort
• Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats
• Risk factors and influence on neurodevelopmental outcomes of neonatal seizures in very low birth weight infants based on nationwide cohort
• Histopathological and functional Characterization of a neonatal mouse model of intraventricular hemorrhage
• Hydrocephalus Pathophysiology and Epidemiology

see Hydrocephalus treatment.

see Posthemorrhagic hydrocephalus of prematurity treatment.

see also Hydrocephalus after aneurysmal subarachnoid hemorrhage treatment

Treatment is limited to surgical diversion of the cerebrospinal fluid (CSF) since no efficient pharmacological therapies are available. This limitation follows from our incomplete knowledge of the molecular mechanisms underlying the ventriculomegaly characteristic of PHH.

Cerebrospinal fluid hypersecretion may contribute to PHH development, likely due to hyperactivity of choroid plexus transporters. The hemorrhage-induced inflammation detected in CSF and in the choroid plexus tissue may represent the underlying pathology. Therapeutic targeting of such pathways may be employed in future treatment strategies towards PHH patients ¹⁾.

Minocycline for hydrocephalus treatment